Micronized progesterone reduces vasoconstriction in the placenta.

Area of Science:

• Obstetrics and Gynecology
• Reproductive Physiology
• Vascular Pharmacology

Background:

• Fetoplacental artery vasoconstriction can impair fetal development.
• Progesterone plays a crucial role in maintaining pregnancy.
• Thromboxane mimetic U46619 is a potent vasoconstrictor used to model vascular changes.

Purpose of the Study:

• To determine if micronized progesterone (P4) can mitigate U46619-induced vasoconstriction in fetoplacental arteries.
• To investigate the potential protective effects of P4 on placental vasculature.

Main Methods:

• Paired human placental cotyledons from five term pregnancies were utilized.
• One cotyledon's fetal artery and intervillous space were perfused with P4, while the other received control perfusate.
• U46619 was administered as a bolus dose to both cotyledons after 30 minutes of perfusion.

Main Results:

• A significant reduction in fetoplacental vascular pressure changes was observed in cotyledons treated with P4 compared to controls (p=0.009).
• P4 infusion attenuated the vasoconstrictive response to U46619.

Conclusions:

• Continuous administration of micronized progesterone effectively attenuates U46619-mediated vasoconstriction in the fetoplacental arteries.
• These findings highlight a potential therapeutic role for P4 in managing conditions involving placental vasoconstriction.